All In Biotech

Drug Trial Radar · NCT06493084

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 Injection in Healthy and Overweight/Obese Subjects

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 25, 2024

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Laekna LimitedIndustry
Sponsor type
Industry
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Conditions

  • Overweight and Obese Volunteers

Interventions

  • LAE102 intravenous administrationDrug

    A single dose of LAE102 administered intravenously

  • placebo intravenous administrationDrug

    A single dose of placebo administered intravenously

  • LAE102 subcutaneous administrationDrug

    Single dose of LAE102 administered subcutaneously

  • placebo subcutaneous administrationDrug

    single dose of placebo administered subcutaneously

  • LAE102 multiple subcutaneous administrationDrug

    Multiple dose of LAE102 administered subcutaneously

  • Placebo multiple subcutaneous administrationDrug

    Multiple dose of placebo administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0Time frame: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan Zhongshan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.